Emma Wilcox

Emma Wilcox

Associate

Employee Benefits and Compensation

Emma Wilcox is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her work focuses on employee benefits and compensation. She supports private and public technology and growth companies with respect to executive compensation and employee benefits matters.

Experience

Education

J.D., J. Reuben Clark Law School, Brigham Young University, 2022
Magna Cum Laude; Editor-in-Chief, BYU Law Review
B.A., English, Brigham Young University, 2018
Magna Cum Laude

Admissions

State Bar of California

Credentials

Education

J.D., J. Reuben Clark Law School, Brigham Young University, 2022
Magna Cum Laude; Editor-in-Chief, BYU Law Review
B.A., English, Brigham Young University, 2018
Magna Cum Laude

Admissions

State Bar of California

Employee Benefits and Compensation

Recent Insights

Client Highlights

On April 24, 2024, IBM and HashiCorp Inc., a leading multi-cloud infrastructure automation company, announced that they have entered into a definitive agreement under which IBM will acquire HashiCorp for $35 per share in cash, representing an enterprise value of $6.4 billion. Wilson Sonsini Goodrich & Rosati is advising HashiCorp on the transaction.

HashiCorp's suite of products provides enterprises with extensive Infrastructure Lifecycle Management and Security Lifecycle Management capabilities to enable organizations to automate their hybrid and multi-cloud environments. IBM’s acquisition continues its deep focus and investment in hybrid cloud and AI, the two most transformational technologies for clients today.

HashiCorp boasts a roster of more than 4,400 clients, including Bloomberg, Comcast, Deutsche Bank, GitHub, J.P Morgan Chase, Starbucks, and Vodafone. HashiCorp's offerings have widescale adoption in the developer community and are used by 85 percent of the Fortune 500. Their community products across infrastructure and security were downloaded more than 500 million times in HashiCorp's FY2024.

The boards of directors of IBM and HashiCorp have both approved the transaction, which is subject to approval by HashiCorp shareholders, regulatory approvals, and other customary closing conditions. The transaction is expected to close by the end of 2024.

The Wilson Sonsini team advising HashiCorp on the acquisition includes:

Learn More

Client Highlights

On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.

Learn More